公开(公告)号：US06291440B1

公开(公告)日：2001-09-18

申请号：US09509454

申请日：2000-03-29

申请人： Hans Berg Andreasen ,  Lars Christensen

发明人： Hans Berg Andreasen ,  Lars Christensen

IPC分类号： A61K3166

CPC分类号： A61K47/61

摘要： An iron-dextran compound for parenteral treatment of iron-deficiency anemia comprises hydrogenated dextran having a weight average molecular weight (Mw) between 700 and 1,400 Daltons, preferably approximately 1,000 Daltons, a number average molecular weight (Mn) of 400 to 1,400 Daltons and wherein 90% by weight of the dextran has molecular weights less than 2,700 Daltons and the Mw of the 10% by weight fraction of the dextran having the highest molecular weights is below 3,200 Daltons, said hydrogenated dextran having been subjected to purification by membrane processes having a cut-off value between 340 and 800 Daltons, in stable association with ferric oxyhydroxide. The compound is produced by using membrane processes to eliminate dextrans of higher molecular weights than approximately 2,700 Daltons and membrane processes to remove saccharides of molecular weights below approximately 340 Daltons from hydrogenated dextran before precipitating ferric hydroxide in the presence of said dextran followed by heat treatment and purification.

摘要翻译： 用于铁缺乏性贫血胃肠外治疗的铁葡聚糖化合物包括重均分子量（Mw）为700至1400道尔顿，优选约1,000道尔顿，数均分子量（Mn）为400至1,400道尔顿的氢化葡聚糖和 其中90重量％的葡聚糖具有小于2,700道尔顿的分子量，并且具有最高分子量的葡聚糖的10重量％分数的Mw低于3,200道尔顿，所述氢化葡聚糖已经通过具有 在340和800道尔顿之间的截止值，与羟基氧化氢稳定相关。 该化合物通过使用膜方法来消除高于约2,700道尔顿的较高分子量的葡聚糖和膜过程，以在所述葡聚糖存在下沉淀氢氧化铁之前从氢化葡聚糖中除去分子量低于约340道尔顿的糖，然后进行热处理， 纯化。

公开(公告)号：US06977249B1

公开(公告)日：2005-12-20

申请号：US09509681

申请日：1999-07-29

申请人： Hans Berg Andreasen ,  Lars Christensen

发明人： Hans Berg Andreasen ,  Lars Christensen

IPC分类号： A61K9/14 ,  A61K9/08 ,  A61K31/295 ,  A61K31/715 ,  A61K31/721 ,  A61K47/12 ,  A61K47/48 ,  A61P3/02 ,  A61P7/06 ,  C08B37/00 ,  C08B37/02 ,  A61K31/70

CPC分类号： C08B37/0021 ,  A61K31/721 ,  A61K47/61

摘要： In a process for producing an iron-dextran compound for use in parenteral treatment of iron-deficiency in humans or animals a stable compound of desired relatively low molecular weight is obtained by using first hydrogenation and then oxidation to convert reducing terminal groups on the dextran molecules before reaction with the iron. By varying the ratio of hydrogenated groups to oxygenated groups the average molecular weight of the resulting iron-dextran compound can be varied.

摘要翻译： 在制备用于人或动物缺铁处理的铁葡聚糖化合物的方法中，通过使用第一氢化然后氧化以转化葡聚糖分子上的还原性末端基团，获得所需相对低分子量的稳定化合物 在与铁反应之前。 通过改变氢化基团与氧化基团的比例，可以改变所得铁 - 葡聚糖化合物的平均分子量。